Uric Acid Nephropathy
No Results
No Results
processing….
Uric acid is the relatively water-insoluble end product of purine nucleotide metabolism. It poses a special problem for humans because of its limited solubility, particularly in the acidic environment of the distal nephron of the kidney. [1] It is problematic because humans do not possess the enzyme uricase, which converts uric acid into the more soluble compound allantoin. Three forms of kidney disease have been attributed to excess uric acid: acute uric acid nephropathy, chronic urate nephropathy, and uric acid nephrolithiasis. These disorders share the common element of excess uric acid or urate deposition, although the clinical features vary. [2]
Uric acid, the product of the xanthine oxidase–catalyzed conversion of xanthine and hypoxanthine, is the final metabolite of endogenous and dietary purine nucleotide metabolism. It is a weak acid, with a p Ka of 5.75; at a physiologic pH of 7.40 in the extracellular compartment, 98% of uric acid is in the ionized form as urate. In the collecting tubules of the kidneys, where the pH can fall to 5.0, uric acid formation is favored.
The critical physical property of uric acid in the clinical setting is solubility. Uric acid is less soluble than urate; thus, an acidic environment decreases solubility. Plasma at a pH of 7.40 is saturated with urate at a concentration of 7 mg/dL. Because normal plasma levels of urate are 3-7 mg/dL for men and 2-6 mg/dL for women, the solubility limit apparently is approached under physiologic conditions. Of the uric acid produced daily, the biliary and gastrointestinal tracts excrete 30% and the kidney excretes 70%.
Renal excretion of uric acid involves 4 pathways: filtration, reabsorption, secretion, and postsecretory reabsorption. Urate is freely filtered at the glomerulus. An active anion-exchange process in the early proximal convoluted tubule reabsorbs most of it. Most urinary uric acid appears to be derived from tubular secretion, possibly from the S2 segment of the proximal tubule. Overall, 98-100% of filtered urate is reabsorbed; 6-10% is secreted, ultimately appearing in the final urine.
Several factors influence the renal handling of urate. Many medications can affect the renal transport of uric acid through effects of proximal tubular absorption and secretion. Extracellular volume expansion or contraction, respectively, enhances or reduces uric acid excretion through the paired movement of sodium. Consequently, in cases of extracellular compartment depletion, urate excretion is diminished.
Physiologically, the major factors that affect urate excretion are the tubular fluid pH, the tubular fluid flow rate, and renal blood flow. The first 2 factors primarily diminish uric acid and urate precipitation in the collecting ducts, while the third is important in urate secretion. In disorders such as sickle cell disease, hypertension, and eclampsia, hyperuricemia out of proportion with decreases in glomerular filtration result from decreased renal blood flow. Organic acids, such as lactic acid and ketoacids, also can impair the proximal secretion of uric acid.
Overproduction of uric acid occurs primarily when tissue breakdown is accelerated. Acute uric acid nephropathy is the term applied to the development of acute oligoanuric renal failure caused by renal tubular obstruction by urate and uric acid crystals. This is observed almost exclusively in the setting of malignancy, especially leukemia and lymphoma, in which rapid cell turnover or cell lysis occurs from chemotherapeutic agents or radiation therapy. [1]
The release of intracellular nucleotides leads to severe hyperuricemia. [3] When urate is filtered at exceedingly high concentrations from the plasma and is further concentrated through the course of the tubular system, with the pH becoming progressively more acidic, uric acid precipitation and obstruction in the tubules, collecting ducts, and even pelves and ureters may result. In animal models of uric acid nephropathy, the precipitation of uric acid and urate occurs primarily in the collecting duct system and, to some extent, in the vasa recta.
Crystal deposition causes increased tubular pressure, increased intrarenal pressure, and extrinsic compression of the small-diameter renal venous network. This causes an increase in renal vascular resistance and a fall in renal blood flow. The elevated tubular pressure and decreased renal blood flow cause a decline in glomerular filtration and can result in acute renal failure.
A widely accepted belief is that the overproduction of uric acid and the presence of hyperuricemia can cause acute kidney failure; however, whether chronic hyperuricemia independently results in chronic interstitial nephritis and progressive kidney failure is less clear.
In patients with chronic hyperuricemia and gout, early studies revealed microtophi formation in the renal medullary interstitium. These deposits were found to contain monosodium urate monohydrate and to be surrounded by a giant cell reaction. Thus, the theory was that urate deposition triggers a foreign body reaction and leads to chronic inflammation and fibrosis. Chronic renal failure from this process was termed chronic uric acid nephropathy, or gouty nephropathy, and articles from the 1960s suggested that all patients with long-standing gout had gouty nephropathy. However, the existence of a chronic urate nephropathy has since been questioned.
In a study of 11,408 consecutive autopsies in Switzerland, only 37 revealed urate deposits in the kidney and only 3 of these cases had otherwise unexplained kidney failure. [4] Investigators also found urate deposition in the kidneys of patients without gout, suggesting that this finding is not specific for gout. In another study, a long-term follow-up evaluation of 524 subjects with gout, the authors concluded that deterioration of kidney function could not be ascribed to hyperuricemia and gout alone. They found that in general, the decline in kidney function could be attributed to other known causes of chronic renal failure, such as nephropathy not associated with uric acid, renal stones, aging, or hypertension. In summary, little compelling evidence exists that chronic hyperuricemia leads to chronic urate nephropathy.
There continues to be considerable interest and debate, however, on the relationship between hyperuricemia, hypertension, and progressive kidney failure. [5, 6, 7] In several prospective cohort trials, hyperuricemia was identified in subjects with normal kidney function at baseline as an independent risk factor for development of chronic kidney disease. [8, 9, 10, 11] A newer hypothesis proposes that hyperuricemia may cause impairment of renal autoregulation, leading to hypertension, microalbuminuria and overt albuminuria, and progressive kidney failure. [12] Moreover, epidemiologic studies in Japan have supported a link between hyperuricemia and progressive kidney disease.
The use of allopurinol [13] to lower uric acid levels has been proposed as a means of retarding the progression of chronic kidney disease and of preventing end-stage renal disease. It has been claimed that at least 1 small, prospective clinical trial demonstrated allopurinol’s efficacy for this purpose. However, the routine use of allopurinol in chronic kidney disease and asymptomatic hyperuricemia is not yet considered to be the standard of care, primarily due to the risk and cost of therapy and the lack of a large, randomized, controlled trial demonstrating the efficacy of uric acid reduction in retarding the progression of chronic kidney disease.
There are 2 other situations in which there appears to be a link between elevated uric acid levels and chronic kidney disease. First, there is evidence that environmental lead exposure is associated with hyperuricemia, gout, hypertension, and chronic kidney disease. [14] Lead exposure may affect urate excretion by the kidney, leading to chronic hyperuricemia and kidney disease. Whether hyperuricemia is the key mechanism for lead-related nephrotoxicity is not clear, however.
Additionally, there is a rare group of patients in which chronic hyperuricemia clearly leads to kidney failure. These are patients with a congenital absence of hypoxanthine guanine phosphoribosyltransferase (HGPRT), a condition that is also known as Lesch-Nyhan syndrome. This is an X-linked disorder that results in mental retardation, involuntary movement, self-mutilation, gout, and early kidney failure. In these patients, chronic uric acid overproduction causes hyperuricemia and uricosuria. The incidence of chronic kidney disease is high in these individuals, who have intratubular uric acid deposits and interstitial urate deposits.
Uric acid stones, which represent 5-10% of all renal calculi in the United States, also result from uric acid precipitation in the collecting system. Uric acid stones are related to uric acid exceeding its solubility in the urine; thus, patients with hyperuricosuria have an increased risk of uric acid nephrolithiasis. Urine oversaturation with uric acid and subsequent crystal formation is determined largely by urinary pH. Individuals who form uric acid stones tend to excrete less ammonium, which contributes directly to low urinary pH. In addition, persons with gout and those who form stones, in particular, have a reduced postprandial alkaline tide (alkaline urinary pH). [15, 16]
United States
The incidence rate of acute uric acid nephropathy is not known. However, some deterioration in renal function secondary to hyperuricemia has been estimated to occur in as many as 10% of patients with leukemia and lymphoma who have undergone intensive chemotherapy and radiation. With prophylactic therapy, however, the occurrence of renal failure requiring dialysis due to acute uric acid nephropathy now appears to be quite rare.
Although chronic urate nephropathy was once thought to be common, studies have indicated that the condition is actually very rare; in fact, its very existence has come into question.
The annual incidence of all renal calculi is 124 cases per 100,000 population. The exact prevalence of uric acid calculi is unknown, but in the United States, the prevalence of all renal calculi in men is 4-9%, and in women is 1.7-4.1%. Uric acid calculi account for 5-10% of all stones in the United States.
Uric acid stones are more common in patients with gout, and the chance of stone formation increases with increasing serum urate levels and urine excretion rates. In one series, 35% of patients with gout who had urinary uric acid levels of 700-1100 mg/d had uric acid calculi; the overall prevalence in persons with primary gout is estimated to be 22%. In a retrospective series, the annual incidence rate of stones in patients with newly diagnosed gout was 1 case per 114 patients.
International
Reported rates vary widely in other countries. In one report from Israel, 75% of all stones were uric acid calculi.
See the list below:
In the 30 cases of acute uric acid nephropathy reported before 1966, the mortality rate was 47%. Subsequent reported cases had a markedly reduced mortality rate, primarily because of the advent of better preventive management and dialysis therapy. In current practice, the prognosis for persons with acute renal failure from acute urate nephropathy is excellent.
The morbidity of uric acid nephrolithiasis arises from the manifestations of stones, obstruction, and crystalluria and is often accompanied by dysuria and hematuria. [17] Secondary bacteriuria and pyelonephritis also can occur. However, life-threatening complications are rare.
See the list below:
A number of different malignancies cause a predisposition to acute uric acid nephropathy, making demographics for this entity difficult to characterize.
See the list below:
Uric acid nephrolithiasis occurs most frequently in those with underlying hyperuricemia or gout, which occurs in men more frequently than women by a male-to-female ratio of 4:1.
In the United States, the prevalence rate is 4-9% in men and 1.7-4.1% in women.
See the list below:
Uric acid nephropathy has been well documented in the pediatric and adult populations. It may occur more often in pediatric patients because of the increased incidence of acute lymphoblastic leukemia and Burkitt lymphoma in this population.
Uric acid nephrolithiasis occurs most frequently in persons with underlying hyperuricemia or gout, which has a peak incidence in the fifth decade of life.
Conger JD. Acute uric acid nephropathy. Med Clin North Am. 1990 Jul. 74(4):859-71. [Medline].
Guest SS. Uric acid and the kidney. Nephrology Rounds 4. Snell Medical Communications; 2001. 1-5.
Dykman D, Simon EE. Hyperuricemia and uric acid nephropathy. Arch Intern Med. 1987 Jul. 147(7):1341-5. [Medline].
Nickeleit V, Mihatsch MJ. Uric acid nephropathy and end-stage renal disease–review of a non-disease. Nephrol Dial Transplant. 1997 Sep. 12(9):1832-8. [Medline]. [Full Text].
Mene P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease?. J Hypertens. 2008 Nov. 26(11):2085-92. [Medline].
Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015 Sep. 33 (9):1729-41; discussion 1741. [Medline].
Kim Y, Shin S, Kim K, Choi S, Lee K. Effect of Urate Lowering Therapy on Renal Disease Progression in Hyperuricemic Patients with Chronic Kidney Disease. J Rheumatol. 2015 Nov. 42 (11):2143-8. [Medline].
Avram Z, Krishnan E. Hyperuricaemia–where nephrology meets rheumatology. Rheumatology (Oxford). 2008 Jul. 47(7):960-4. [Medline].
Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004 Oct. 44(4):642-50. [Medline].
Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008 Jul. 75 Suppl 5:S13-6. [Medline]. [Full Text].
Kanbay M, Yilmaz MI, Sonmez A, Solak Y, Saglam M, Cakir E, et al. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol. 2012. 36(4):324-31. [Medline].
Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link?. J Am Soc Nephrol. 2005 Jul. 16(7):1909-19. [Medline]. [Full Text].
Pea F. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. Contrib Nephrol. 2005. 147:35-46. [Medline].
Lin JL, Yu CC, Lin-Tan DT, et al. Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout. Kidney Int. 2001 Jul. 60(1):266-71. [Medline]. [Full Text].
Kim YJ, Kim CH, Sung EJ, Kim SR, Shin HC, Jung WJ. Association of nephrolithiasis with metabolic syndrome and its components. Metabolism. 2013 Jun. 62(6):808-13. [Medline].
Emami-Naini A, Eshraghi A, Shahidi S, Mortazavi M, Seyrafian S, Roomizadeh P, et al. Metabolic evaluation in patients with nephrolithiasis: A report from Isfahan, Iran. Adv Biomed Res. 2012. 1:65. [Medline]. [Full Text].
Roncal-Jimenez C, García-Trabanino R, Barregard L, Lanaspa MA, Wesseling C, Harra T, et al. Heat Stress Nephropathy From Exercise-Induced Uric Acid Crystalluria: A Perspective on Mesoamerican Nephropathy. Am J Kidney Dis. 2015 Oct 5. [Medline].
Bainbridge SA, Deng JS, Roberts JM. Increased xanthine oxidase in the skin of preeclamptic women. Reprod Sci. 2009 Feb 5. [Medline].
Mukherjee E, Mukherji D, Jayawardene SA, et al. Tumor lysis syndrome and acute renal failure–an increasing spectrum of presentations. Clin Nephrol. 2007 Sep. 68(3):186-9. [Medline].
Fagugli RM, Gentile G, Ferrara G, et al. Acute renal and hepatic failure associated with allopurinol treatment. Clin Nephrol. 2008 Dec. 70(6):523-6. [Medline].
Ueng S. Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc (Bayl Univ Med Cent). 2005 Jul. 18(3):275-9. [Medline]. [Full Text].
Hochberg J, Cairo MS. Rasburicase: future directions in tumor lysis management. Expert Opin Biol Ther. 2008 Oct. 8(10):1595-604. [Medline].
Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008 Oct 23. 359(17):1811-21. [Medline].
Mark T Fahlen, MD Private Practice, Mark T Fahlen, MD, Inc
Mark T Fahlen, MD is a member of the following medical societies: American College of Physicians, Renal Physicians Association
Disclosure: Nothing to disclose.
Mahendra Agraharkar, MD, MBBS, FACP, FASN Clinical Associate Professor of Medicine, Baylor College of Medicine; President and CEO, Space City Associates of Nephrology
Mahendra Agraharkar, MD, MBBS, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Nephrology, National Kidney Foundation
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Eleanor Lederer, MD, FASN Professor of Medicine, Chief, Nephrology Division, Director, Nephrology Training Program, Director, Metabolic Stone Clinic, Kidney Disease Program, University of Louisville School of Medicine; Consulting Staff, Louisville Veterans Affairs Hospital
Eleanor Lederer, MD, FASN is a member of the following medical societies: American Association for the Advancement of Science, American Federation for Medical Research, American Society for Biochemistry and Molecular Biology, American Society for Bone and Mineral Research, American Society of Nephrology, American Society of Transplantation, International Society of Nephrology, Kentucky Medical Association, National Kidney Foundation, Phi Beta Kappa
Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: American Society of Nephrology<br/>Received income in an amount equal to or greater than $250 from: Healthcare Quality Strategies, Inc<br/>Received grant/research funds from Dept of Veterans Affairs for research; Received salary from American Society of Nephrology for asn council position; Received salary from University of Louisville for employment; Received salary from University of Louisville Physicians for employment; Received contract payment from American Physician Institute for Advanced Professional Studies, LLC for independent contractor; Received contract payment from Healthcare Quality Strategies, Inc for independent cont.
Vecihi Batuman, MD, FASN Huberwald Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Renal Section, Southeast Louisiana Veterans Health Care System
Vecihi Batuman, MD, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, International Society of Nephrology, Southern Society for Clinical Investigation
Disclosure: Nothing to disclose.
Uric Acid Nephropathy
Research & References of Uric Acid Nephropathy|A&C Accounting And Tax Services
Source